8-K: INVO Fertility Reports 17% Revenue Growth in Q2 2026

INVO Fertility announced second quarter 2026 results, showing a 17% increase in revenue to $2.18 million and profitability at the clinic platform level.

Summary

• INVO Fertility reported a 17% increase in revenue for the second quarter of 2026, reaching $2,175,485, up from $1,863,654 in the same period last year.
• Consolidated clinic revenue grew by 18% to $2,167,785.
• Clinic-Level Adjusted EBITDA (before corporate expenses) was approximately $333,000 in Q2 2026, an improvement from $164,000 in Q1 2026.
• The company reported a net income of $0.9 million for Q2 2026, a significant improvement from a net loss of $(3.6) million in Q2 2025.
• This net income includes a $2.5 million gain on remeasurement related to the Birmingham acquisition.
• Adjusted EBITDA was $(1.0) million for Q2 2026, compared to $(0.6) million in Q2 2025.
• Cash reserves stood at $3.7 million as of June 30, 2026.
• The company acquired full ownership of its Birmingham, Alabama fertility clinic in June 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with revenue growth and improved clinic-level profitability indicating a strengthening operational performance, despite ongoing corporate expenses.

Positives

• Revenue increased by 17% to $2,175,485 in Q2 2026 compared to Q2 2025.
• Clinic-Level Adjusted EBITDA improved to approximately $333,000 in Q2 2026, demonstrating growing profitability at the operational level.
• Net income turned positive at $0.9 million in Q2 2026, a substantial turnaround from a net loss of $(3.6) million in Q2 2025.
• The acquisition of full ownership of the Birmingham clinic provides greater operational control and economic participation.
• The company is actively pursuing a disciplined acquisition strategy focused on established, profitable fertility practices.
• Investments in platform capabilities (operations, HR, finance) are being made to support expansion and integration.
• Clinical research and innovation are highlighted, with presentations at a major symposium.
• Cash position improved to $3.7 million at the end of Q2 2026.

Negatives

• Adjusted EBITDA remained negative at $(1.0) million for Q2 2026, indicating ongoing corporate-level losses.
• The net income of $0.9 million was significantly influenced by a $2.5 million gain on remeasurement from the Birmingham acquisition.
• Cost of services increased due to the addition of Family Beginnings and one-time staffing costs at the Georgia clinic.
• Selling, general, and administrative expenses, while decreased, were still substantial at $1.9 million in Q2 2026.

Risks

• The company is under no obligation to update or alter its forward-looking statements, which could lead to investors relying on outdated information.
• Factors detailed in SEC filings could cause actual results to differ materially from forward-looking statements.
• Integration of acquired clinics and scaling of the platform present operational challenges.
• Reliance on acquisitions for growth introduces risks associated with due diligence and integration success.

Future Outlook

The company intends to drive organic growth across its existing clinic network, leverage its corporate infrastructure across a larger revenue base, and pursue disciplined acquisitions of established, profitable fertility practices. Management believes INVO is well-positioned to build a scaled fertility services company and create long-term value.

Management Comments

• "The second quarter continued the progress we demonstrated in the first quarter and provided further validation of our strategy."
• "Revenue increased 17% supported by the first full-quarter contribution from Family Beginnings and continued growth initiatives across our clinic network."
• "Just as importantly, the clinic platform remained profitable on an Adjusted EBITDA basis before corporate operating and public company expenses, generating approximately $333,000 during the second quarter and $0.95 million during fiscal 2025."
• "We believe these results demonstrate both the underlying earnings power of the clinics we have assembled and the value of building a larger platform around them."
• "Our objective is to pair strong local clinical teams with the support, capabilities, and best practices needed to grow patient volumes, broaden services, improve execution and make each clinic more successful as part of the INVO family."
• "With a growing operating platform, demonstrated clinic-level Adjusted EBITDA generation, an improved financial position, and a robust pipeline of opportunities, we believe INVO is increasingly well positioned to build a scaled fertility services company and create meaningful long-term value."

Industry Context

StockSavvy.ai notes that the fertility services industry is characterized by consolidation and a focus on operational efficiency. INVO Fertility's strategy of acquiring profitable clinics and investing in shared services aligns with broader industry trends aimed at achieving scale and profitability in a competitive market.

Stakeholder Impact

• Shareholders: Potential for increased long-term value as the company scales and improves profitability. The positive revenue growth and clinic-level profitability are encouraging signs.
• Employees: Investments in shared services and platform capabilities may lead to more standardized HR and operational support across clinics.
• Customers: Continued focus on clinical research and physician expertise aims to improve patient care and outcomes.
• Suppliers: Increased operational scale may lead to greater purchasing power for clinic supplies.

Next Steps

• Continue to drive organic growth across the existing clinic network.
• Leverage corporate infrastructure across a larger revenue base.
• Pursue disciplined acquisitions of established, profitable fertility practices.
• Build capabilities across operations, human resources, and finance to support a larger clinic network and improve execution.
• Present clinical research and innovation findings.

Key Dates

Recommendation

The filing shows positive revenue growth and improved clinic-level profitability, which are encouraging. However, the overall Adjusted EBITDA remains negative, and the net income was significantly boosted by a one-time gain. While the strategy appears sound and execution is improving, further evidence of sustained profitability and a clear path to positive overall Adjusted EBITDA is needed before a stronger recommendation can be made.

Keywords

fertility, IVF, clinic acquisition, revenue growth, EBITDA, healthcare services, ART, INVOcell